Colchicine therapy for deep vein thrombosis in a patient with vascular-type Behçet disease: A case report.
Adult
Anticoagulants
/ therapeutic use
Asian People
/ ethnology
Behcet Syndrome
/ complications
Colchicine
/ administration & dosage
Computed Tomography Angiography
/ methods
Drug Therapy, Combination
Edema
/ diagnosis
Humans
Leg
/ physiopathology
Lung
/ blood supply
Male
Pain
/ diagnosis
Pulmonary Artery
/ pathology
Thrombosis
/ drug therapy
Treatment Outcome
Tubulin Modulators
/ administration & dosage
Venous Thrombosis
/ drug therapy
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
22
4
2020
pubmed:
22
4
2020
medline:
24
4
2020
Statut:
ppublish
Résumé
Behçet Disease (BD) is a chronic inflammatory vasculitis with thrombogenicity and multisystem involvement. Deep vein thrombosis (DVT) in the lower extremities is the most frequent manifestation of vascular involvement in BD. The causes of thrombosis vary widely and include congenital predisposition and acquired factors, but of all the thrombosis, the cause is rarely BD. Furthermore, there are few reports of treatment for thrombosis in BD. We herein describe the case of an Asian male patient aged 40 years, admitted to our hospital for left leg pain, edema, and swelling. We confirmed the DVT and pulmonary artery thrombosis (PAT) by contrast computed tomography angiogram. At the same time, the patient developed oral ulcerations and skin lesions consistent with BD. The patient was initially treated with anticoagulants. However, because the improvement of DVT was inadequate, we added colchicine in anticipation of anti-inflammatory effects. After that, anticoagulation was discontinued, and only colchicine was continuously prescribed. We observed an almost complete resolution of DVT and PAT with no recurrence of thrombosis for 6 months after discharge. This case shows us that we should consider BD as a differential diagnosis of DVT and that colchicine therapy is effective for inflammation-induced thrombosis in BD.
Identifiants
pubmed: 32312000
doi: 10.1097/MD.0000000000019814
pii: 00005792-202004170-00084
pmc: PMC7220338
doi:
Substances chimiques
Anticoagulants
0
Tubulin Modulators
0
Colchicine
SML2Y3J35T
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e19814Références
Rokutanda R, Kishimoto M, Okada M. Update on the diagnosis and management of Behçet's disease. Open Access Rheumatol 2014;30:1–8.
Branchford BR, Carpenter SL. The role of inflammation in venous thromboembolism. Front Pediatr 2018;6:142.
La Regina M, Gasparyan AY, Orlandini F, et al. Behçet's disease as a model of venous thrombosis. Open Cardiovasc Med J 2010;23:71–7.
Nair JR, Moots RJ. Behcet's disease. Clin Med (Lond) 2017;17:71–7.
Yurdakul S, Hamuryudan V, Yazici H. Behçet syndrome. Curr Opin Rheumatol 2004;16:38–42.
Masuda K, Inaba G, Mizushima H, et al. A nation-wide survey of Behçet's disease in Japan. Jpn J Ophthalmol 1975;19:278–85.
Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60–76.
Ishibashi H. What is vascular Behçet's disease? Ann Vasc Dis 2018;11:52–6.
Hosokawa K, Fujiwara M, Mukai Y, et al. Isolated venous thrombosis of inferior vena cava presenting Budd-Chiari syndrome associated with Behçet's disease. Eur Heart J 2015;36:2661.
Malik GH, Sirwal IA, Pandit KA. Behcet's syndrome associated with minimal change glomerulonephritis and renal vein thrombosis. Nephron 1989;52:87–9.
Krumb E, Lefebvre C, Peeters A, et al. Cerebral venous thrombosis revealing Behçet's disease in a Moroccan patient: a case report and literature review. SAGE Open Med Case Rep 2018;28:62050313X18767053. doi: 10.1177/2050313X18767053. eCollection 2018.
doi: 10.1177/2050313X18767053.
Wu X, Li G, Huang X, et al. Behçet's disease complicated with thrombosis: a report of 93 Chinese cases. Medicine (Baltimore) 2014;93:e263.
Nishida T, Hakuno D. Images in clinical medicine. Endocardial calcification in Behçet's disease. N Engl J Med 2013;369:e28.
Onder M, Gürer MA. The multiple faces of Behçet's disease and its aetiological factors. J Eur Acad Dermatol Venereol 2001;15:126–36.
Ozoran K, Dügün N, Gürler A, et al. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. Scand J Rheumatol 1995;24:376–82.
Chafa O, Fischer AM, Meriane F, et al. Behçet syndrome associated with protein S deficiency. Thromb Haemost 1992;67:1–3.
Ghaffari S, Pourafkari L, Javadzadegan H, et al. Mean platelet volume is a predictor of ST resolution following thrombolysis in acute ST elevation myocardial infarction. Thromb Res 2015;136:101–6.
Ataş H, Canpolat F, Eskioglu F. Evaluation of mean platelet volume in patients with Behcet's disease as an indicator of vascular thrombosis. Arch Iran Med 2018;21:234–9.
Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2013;108:1284–97.
Khan E, Ambrose NL, Ahnström J, et al. A low balance between microparticles expressing tissue factor pathway inhibitor and tissue factor is associated with thrombosis in Behçet's syndrome. Sci Rep 2016;7:38104doi: 10.1038/srep38104.
doi: 10.1038/srep38104
Becatti M, Emmi G, Silvestri E, et al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet disease. Circulation 2016;133:302–11.
Hatemi G, Seyahi E, Fresko I, et al. One year in review 2018: Behçet's syndrome. Clin Exp Rheumatol 2018;36: (6 Suppl 115): 13–27.
Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008;67:1656–62.
Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood 2017;129:3285–93.
Deftereos S, Giannopoulos G, Papoutsidakis N, et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol 2013;62:1817–25.
Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995;96:994–1002.
Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237–41.
Ataş H, Cemil BC, Canpolat F, et al. The effect of colchicine on mean platelet volume in Behcet's disease. Ann Clin Lab Sci 2015;45:545–9.
Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001;44:2686–92.
Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009;19:542–9.
Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999;33:1424–6.